Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome in which the marrow essentially stops producing enough blood cells — red cells, white cells, and platelets — all at once. Without treatment, the median survival is roughly 3 to 6 months. But here’s the critical thing to know: with modern therapy, including bone marrow transplantation or immunosuppressive regimens, 5-year survival rates now reach 70–80% or higher in many patient populations.
If you or someone you care about has just received this diagnosis, the prognosis is far better today than it was even 20 years ago. The key is rapid, accurate diagnosis and getting to a hematologist — ideally at a center experienced in bone marrow failure — as quickly as possible.
What Exactly Happens in Severe Aplastic Anemia?
Your bone marrow is a factory that produces roughly 200 billion red blood cells, 10 billion white blood cells, and 400 billion platelets every single day. In SAA, that factory shuts down. The marrow space that should be packed with blood-forming stem cells instead fills with fat cells.
In about 70% of cases, this destruction is autoimmune — your own T-lymphocytes attack and destroy the hematopoietic stem cells. The remaining cases are linked to identifiable triggers or inherited conditions, but a significant portion (roughly 50% overall) are labeled idiopathic, meaning no specific cause is found.
Diagnostic Criteria: How SAA Is Defined
SAA isn’t just “low blood counts.” It has specific, internationally recognized diagnostic criteria based on the Camitta criteria. You need bone marrow cellularity below 25% on biopsy, plus at least two of the following three peripheral blood findings:
| Parameter | Severe Aplastic Anemia | Very Severe Aplastic Anemia | Normal Range |
|---|---|---|---|
| Absolute Neutrophil Count (ANC) | < 500/µL | < 200/µL | 1,500–8,000/µL |
| Platelet Count | < 20,000/µL | < 20,000/µL | 150,000–400,000/µL |
| Reticulocyte Count | < 20,000/µL (absolute) | < 20,000/µL (absolute) | 25,000–125,000/µL |
| Bone Marrow Cellularity | < 25% | < 25% | 30–70% (age-dependent) |
The distinction between “severe” and “very severe” aplastic anemia (vSAA) matters clinically — patients with an ANC below 200/µL face substantially higher infection risk and worse outcomes without urgent intervention.
Causes and Known Risk Factors
While the autoimmune mechanism dominates, several triggers and associations are well established:
- Medications: Chloramphenicol, carbamazepine, phenytoin, sulfonamides, and NSAIDs have all been implicated. Drug-induced cases account for roughly 10–15% of diagnoses.
- Viral infections: Hepatitis-associated aplastic anemia (usually seronegative hepatitis, not hepatitis A, B, or C) occurs in about 5–10% of cases. Epstein-Barr virus, CMV, and parvovirus B19 are also linked.
- Chemical exposures: Benzene and other organic solvents are classic culprits, particularly with occupational exposure.
- Inherited syndromes: Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome can present as aplastic anemia, especially in younger patients. Genetic testing is essential in patients under 40.
- Pregnancy: Rare, but pregnancy-associated aplastic anemia is a recognized entity that sometimes resolves after delivery.
Globally, SAA affects approximately 2 per million people per year in Western countries, but rates are 2–3 times higher in East Asia, suggesting both genetic susceptibility and environmental factors play a role.
Symptoms That Should Raise Alarm
The symptoms of SAA reflect the specific cell lines that are depleted:
- Low red blood cells (anemia): Progressive fatigue, pallor, shortness of breath on exertion, dizziness, rapid heart rate
- Low white blood cells (neutropenia): Recurrent or severe infections, fevers, mouth ulcers that won’t heal
- Low platelets (thrombocytopenia): Easy bruising, petechiae (pinpoint red spots on the skin), prolonged bleeding from minor cuts, heavy menstrual periods, nosebleeds
What makes SAA distinctive from less serious causes of low blood counts is the combination of all three. A patient who bruises easily, feels exhausted, and keeps getting infections should have a complete blood count drawn immediately.
Treatment: Two Main Strategies
1. Bone Marrow (Stem Cell) Transplant
For patients under 40 with a matched sibling donor, allogeneic hematopoietic stem cell transplant (HSCT) is the first-line treatment. Cure rates exceed 90% in children and 75–80% in younger adults with matched sibling donors. This is the only truly curative option.
For patients without a sibling match, matched unrelated donor (MUD) transplants and haploidentical transplants have improved dramatically. Recent data using post-transplant cyclophosphamide protocols show survival rates approaching those of sibling transplants in experienced centers.
2. Immunosuppressive Therapy (IST)
For patients over 40, or those without a suitable donor, the standard regimen is horse antithymocyte globulin (hATG) combined with cyclosporine. Response rates are approximately 60–70% at 6 months. The addition of eltrombopag (a thrombopoietin receptor agonist) to frontline IST has been a game-changer — a landmark NIH study showed overall response rates of 85–94% when eltrombopag was added to the standard hATG/cyclosporine backbone.
One critical caveat: rabbit ATG (Thymoglobulin) is not interchangeable with horse ATG (ATGAM) in this setting. Randomized trials have shown horse ATG is significantly superior for aplastic anemia, despite rabbit ATG being preferred in transplant conditioning.
Supportive Care
While definitive treatment is being arranged, patients typically need:
- Red blood cell and platelet transfusions (though minimizing transfusions before transplant is ideal to reduce alloimmunization)
- Prophylactic antifungals and antibiotics when the ANC is critically low
- Iron chelation therapy for patients who become iron-overloaded from repeated transfusions
When to See a Doctor
Seek medical attention urgently if you experience:
- Unexplained fatigue combined with easy bruising or frequent infections
- Petechiae or purpura appearing on your skin without trauma
- A fever above 100.4°F (38°C) when you’re known to have low blood counts
- Bleeding that doesn’t stop with normal pressure
If you’ve already been diagnosed with moderate aplastic anemia, any worsening of blood counts warrants re-evaluation — progression to severe disease changes the treatment approach entirely.
Frequently Asked Questions
Is severe aplastic anemia a type of cancer?
No. SAA is a bone marrow failure syndrome, not a malignancy. However, patients with SAA do have an elevated long-term risk (10–15% over 10 years) of developing clonal disorders such as myelodysplastic syndrome (MDS) or paroxysmal nocturnal hemoglobinuria (PNH), which is why lifelong monitoring is essential.
What is the life expectancy with severe aplastic anemia?
With modern treatment, the 5-year survival rate is approximately 70–80%. Younger patients who receive a matched sibling transplant have the best outcomes, with long-term survival exceeding 90%. Even older patients on immunosuppressive therapy can achieve durable responses lasting decades. Untreated, however, SAA is usually fatal within months.
Can severe aplastic anemia come back after treatment?
After transplant, relapse is uncommon (under 5–10%). After immunosuppressive therapy, roughly 30–40% of responders will relapse and require additional treatment. A second course of IST or a transplant may be considered at that point.
Is severe aplastic anemia hereditary?
Most cases are acquired and autoimmune, not inherited. However, inherited bone marrow failure syndromes like Fanconi anemia can mimic SAA. Genetic testing — including telomere length assessment and chromosomal breakage studies — is recommended for patients diagnosed before age 40, and increasingly for older patients as well.
What’s the difference between aplastic anemia and severe aplastic anemia?
The difference is defined by specific blood count thresholds. Non-severe (moderate) aplastic anemia has low counts that don’t meet the Camitta criteria listed above. This distinction is clinically significant: moderate aplastic anemia may be observed or treated with cyclosporine alone, while SAA requires aggressive intervention with transplant or combination immunosuppressive therapy.
